GT
AKBA icon

Glenmede Trust’s Akebia Therapeutics AKBA Stock Holding History

Glenmede Trust’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-5,454
Closed -$13K – 1221
2020
Q3 		$13K Buy
5,454
+3,069
+129% +$26.9K ﹤0.01% 1764
2020
Q2 		$32K Sell
2,385
-2,121
-47% -$21.9K ﹤0.01% 1423
2020
Q1 		$28K Hold
4,506
– – ﹤0.01% 1909
2019
Q4 		$28K Sell
4,506
-1,341
-23% -$6.37K ﹤0.01% 1909
2019
Q3 		$22 Sell
5,847
-363
-6% -$1.56K ﹤0.01% 1992
2019
Q2 		$29 Hold
6,210
– – ﹤0.01% 1915
2019
Q1 		$49 Buy
6,210
+1,704
+38% +$11.7K ﹤0.01% 1691
2018
Q4 		$24 Buy
+4,506
New +$35.3K ﹤0.01% 1904

Other funds holding AKBA

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Glenmede Trust's AKBA Position: Q4 2020 in Review

Glenmede Trust sold out of Akebia Therapeutics (AKBA) in Q4 2020, closing a stake of 5,454 shares — an estimated $13K sold.

Glenmede Trust first reported a position in AKBA in Q4 2018 and held it in 8 quarters. The position peaked at $32K in Q2 2020. 143 funds tracked by Wall St. Rank hold AKBA as of Q4 2020.

  • Glenmede Trust reported no remaining Akebia Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Glenmede Trust sold 5,454 Akebia Therapeutics shares in Q4 2020, an estimated $13K.
  • Glenmede Trust first reported a position in Akebia Therapeutics in Q4 2018 and held it in 8 quarters.
  • Glenmede Trust's Akebia Therapeutics position peaked at $32K in Q2 2020.
  • 143 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.